Selinexor, a Nuclear Export Inhibitor, Added to Standard Intensive Treatment for Elderly Patients With AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
Leukemia 2022 Jul 22;[EPub Ahead of Print], JJWM Janssen, B Löwenberg, M Manz, BJ Biemond, PE Westerweel, SK Klein, M Fehr, HAM Sinnige, A Efthymiou, MCJC Legdeur, T Pabst, M Gregor, MWM van der Poel, D Deeren, LW Tick, M Jongen-Lavrencic, F van Obbergh, RS Boersma, O de Weerdt, Y Chalandon, D Heim, O Spertini, G van Sluis, C Graux, G Stüssi, Y van Norden, GJ OssenkoppeleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.